Millennium

Millennium (a.k.a. The Takeda Oncology Co.) has added Claire Thom, Pharm.D. as senior vice president, portfolio management and Isabelle Mercier as vice president, marketing for Millennium’s commercial organization.
   
“We are very excited to have these two, highly-successful pharmaceutical executives join the Millennium team to help lead the organization towards becoming a top three global oncology company,” said Deborah Dunsire, M.D., president and chief executive officer, Millennium. “Claire and Isabelle will offer insight and perspective to effectively develop and market the molecules in our expanding oncology pipeline as well as bring a proven level of entrepreneurship and innovative thinking.”
   
Dr. Thom joins Millennium with nearly 20 years of experience in drug development, new product planning and marketing. She will be responsible for the oncology portfolio management process. Previously, Ms. Thom was responsible for the oversight and implementation of the global therapeutic area strategies for oncology, urology and gynecology franchises of Takeda Pharmaceutical Co. in Japan. She also held several senior R&D and product planning positions at Takeda Global R&D and Takeda Pharmaceuticals North America. Prior to Takeda, she held positions of increasing responsibility at G.D. Searle and Co. in the areas of global new product planning and U.S. oncology marketing.  
   
Ms. Mercier brings more than 16 years of global pharmaceutical marketing experience. She will lead and develop U.S. and global marketing strategy for the commercialization of late phase development products as well as marketed oncology products, including Velcade for Injection for patients with multiple myeloma. She joins the company from Sanofi-Aventis and most recently served as vice president of Taxotere Marketing. She also has global experience in sales, clinical research and oncology product launches from Sanofi-Synthelab and SangStat Medical Corp.